India to Brunei Pharmaceutical Export (2026) — $287.7K, 28 Suppliers | TransData Nexus

India to Brunei Pharmaceutical Export (2026) — $287.7K, 28 Suppliers | TransData Nexus | TransData Nexus

Top Pharmaceutical Formulations — India to Brunei

#	Formulation	Value	Share
1	Proglutrol 500 (mal10110013a)	$83.9K	29.2%
2	Levetiracetam 500 MG Tablets Batch No Lv225001a Mfg Date 01.04.2025 Exp Date 31…	$29.6K	10.3%
3	Amoxicillin and Potassium Clavulanate Fo	$27.8K	9.7%
4	Pharmaceutical Drugs and Medicine - Carbopa - 450 450mg/45ml Vial As Per Invoice	$13.7K	4.7%
5	Contain Medicines Harmless Pharmaceutical Products - Contrapaque 350injection (…	$13.3K	4.6%
6	Contain Medicines Harmless Pharmaceutical Products -bravecto 1000mg 20-40 Kg Ta…	$12.9K	4.5%
7	Calcitriol Capsules 0.5mcg Soft Gelatinus (2016 X 100s)	$6.8K	2.4%
8	Multibacter 500 Gm ,probiotic Cultures of	$6.4K	2.2%
9	Contain Medicines Harmless Pharmaceutical Products Bravecto 1000mg 20 40 Kg Tab…	$5.5K	1.9%
10	Not for Human Use. Veterinary Pharmaceut	$4.5K	1.6%
11	Calcitriol Capsules 0.5mcg Soft Gelatinus (1248 X 100s)	$4.2K	1.5%
12	Intrauterine Contraceptive Device Iud Tcu 380ag Normal with Probe Catch Cover	$3.8K	1.3%
13	Ce Marked-intrauterine Device (iud): Tcu380ag Normal with Probe (catch Cover)	$3.8K	1.3%
14	Pond Bio 500 Gm, Probiotic Cultures of	$3.7K	1.3%
15	Globivac Ibh-1000 Doses (batch No:e24023)	$3.1K	1.1%

India exports 19+ pharmaceutical formulations to Brunei with a combined trade value of $287.7K. Key products include Metformin ($84K), Amoxicillin ($28K), Device ($4K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 205 verified Indian Customs (DGFT) shipment records.

Top Pharmaceutical Products — India to Brunei Trade Routes

1Metformin$84K

2Amoxicillin$28K

3Device$4K

These are the top pharmaceutical products exported from India to Brunei, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Brunei buyers, regulatory requirements, and logistics for that specific product corridor. Products include Metformin ($84K), Amoxicillin ($28K), Device ($4K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.

Top Indian Exporters to Brunei

1Inventia Healthcare Limited

$84K

2Jubilant Generics Limited

$30K

3Vea Impex (i) Private Limited

$28K

4Medreich Limited

$28K

5Grameen Pharma Llp

Port Analysis — India to Brunei Pharmaceutical Shipments

Indian Export Ports

JNPT1.5%

SAHAR AIR CARGO ACC (INBOM4)44.4%

DELHI AIR CARGO ACC (INDEL4)3.9%

SAHAR AIR19.0%

BANGALORE ICD (INWFD6)0.5%

Brunei Import Ports

BANDAR SERI B78.5%

MUARA6.8%

Muara6.8%

BENNETTSVI1.5%

DAR ES SALAM (DARESS2.0%

Trade Statistics

Total Value$288K

Shipments205

Indian Exporters28

Brunei Buyers28

Avg Shipment$1K

Products125

Other Destinations

United States$8.8B United Kingdom$1.2B Canada$1.1B France

Last updated: March 28, 2026

India–Brunei Pharmaceutical Trade Corridor Analysis

Historical evolution, India's market position, and recent developments

1Trade Corridor Evolution

The pharmaceutical trade between India and Brunei has experienced gradual growth over the years. In 2024, India exported pharmaceutical products valued at approximately $377,250 to Brunei, marking a significant increase from $59,590 in 2023. This upward trajectory reflects India's expanding presence in Brunei's pharmaceutical market.

The trade is characterized by a diverse range of products, with the top ten items accounting for 70% of the total export value. Notably, PROGLUTROL 500 (Metformin Hydrochloride Extended Release Tablets USP 500 mg) leads with a 29.2% share, followed by Levetiracetam 500 mg Tablets at 10.3%. This product diversity indicates a tailored approach to meet Brunei's specific pharmaceutical needs.

2India's Market Position

India's pharmaceutical exports to Brunei, totaling $377,250 in 2024, represent a modest portion of Brunei's overall pharmaceutical imports, which stood at $812,800 in the same year. While India's share is relatively small, the consistent growth and product diversification underscore its strategic importance in Brunei's pharmaceutical supply chain.

3Recent Developments

Brunei Regulatory Landscape for Indian Pharmaceutical Exports

Registration process, GMP requirements, import documentation

1Registration Process

To register pharmaceutical products in Brunei, Indian companies must adhere to the guidelines set by the Department of Pharmaceutical Services under the Ministry of Health. The registration process involves submitting a comprehensive dossier that includes administrative data, product information, and certifications. The dossier should be organized as follows:

Section A: Table of Contents
Application Form (Form No.: BDMCA/DPS/01): Complete all sections in English and/or Malay.
Letter of Authorization: A copy from the product owner or manufacturer authorizing the applicant to register the medicinal product.
Certifications:
For imported products:
License of pharmaceutical industries/importer/wholesaler.
Certificate of Pharmaceutical Product (CPP) issued by the competent authority in the country of origin, according to the current WHO format (Original).
Site Master File of the manufacturer (Optional).
Labelling: Samples or proposed drafts of product labelling in English and/or Malay for unit cartons, inner labels, and blister/strips (if applicable).
Product Information: Samples or proposed drafts of product information in English and/or Malay, including Summary of Product Characteristics (SmPC) or Package Inserts (for generic products), SmPC (for New Chemical Entities and Biotechnology products), and Patient Information Leaflets (PIL) (for OTC products).

The checklist provided with the application form should be completed and attached at the front of each application form upon submission to the Drug Registration Unit. (moh.gov.bn)

Regarding the dossier format, Brunei does not explicitly mandate the use of the Common Technical Document (CTD), ASEAN Common Technical Dossier (ACTD), or electronic Common Technical Document (eCTD). However, the dossier must be comprehensive and adhere to the guidelines provided by the Department of Pharmaceutical Services. (moh.gov.bn)

The approval timeline and fees for product registration in Brunei are not specified in the available sources. It is advisable for Indian pharmaceutical companies to contact the Department of Pharmaceutical Services directly for detailed information on processing times and associated fees.

2GMP & Facility Requirements

Brunei requires that pharmaceutical products imported into the country be manufactured in facilities that comply with Good Manufacturing Practice (GMP) standards recognized by the World Health Organization (WHO). Manufacturing facilities in India seeking to export to Brunei must ensure that their operations meet these international GMP standards. This includes maintaining proper documentation, ensuring equipment calibration, and adhering to stringent quality control measures. The inspection process involves the Department of Pharmaceutical Services evaluating the manufacturing facility's compliance with GMP standards. While Brunei may not have a mutual recognition agreement with India, adherence to WHO-GMP standards is crucial for market access.

3Import Documentation

To import pharmaceutical products into Brunei, companies must obtain an Import Licence and a Wholesaler’s Licence from the Department of Pharmaceutical Services. The Import Licence is valid for one year and requires compliance with all relevant provisions under the Medicines Order, 2007, and its related regulations. Applicants must submit a complete application form along with supporting documents, including:

Business Registration Certificate or Certificate of Incorporation.
Statement from the exporter confirming registration as a pharmaceutical dealer in the exporting country.
Documentary evidence showing that the product is registered in the exporting country.
Certificate of Analysis of the product from the manufacturer or an approved local testing laboratory.
An undertaking from the applicant accepting responsibility for the quality, safety, and efficacy of the product.

Importers are also required to report any changes in their business details, arrange tests and submit samples as requested by the Authority, and inform the Authority of any adverse effects resulting from the use of the medicinal product. (moh.gov.bn)

TransData Nexus Research · Brunei regulatory databasesMar 2026

Product Categories & Therapeutic Trends — India to Brunei

Dominant categories, emerging opportunities, and demand drivers

1Dominant Categories

India's pharmaceutical exports to Brunei are predominantly concentrated in therapeutic areas addressing chronic conditions, notably diabetes and epilepsy. The leading product, PROGLUTROL 500 (Metformin Hydrochloride Extended Release Tablets USP 500 mg), accounts for 29.2% of the total export value, underscoring the significant demand for diabetes management medications in Brunei. This aligns with Brunei's healthcare priorities, as the Ministry of Health has identified the prevention and control of non-communicable diseases, including diabetes, as a key strategy.

The second most exported product, Levetiracetam 500 mg Tablets, comprising 10.3% of the export value, indicates a substantial market for epilepsy treatments. This is consistent with Brunei's healthcare focus on providing comprehensive services for chronic conditions. The presence of multiple Indian exporters, such as Inventia Healthcare Limited and Jubilant Generics Limited, reflects India's capacity to meet Brunei's demand for these essential medications.

2Emerging Opportunities

Brunei's pharmaceutical market presents emerging opportunities for Indian exporters, particularly in the realm of biosimilars. The establishment of Simpor Pharma, Brunei's first pharmaceutical manufacturing plant, signifies a growing interest in local production and the potential for biosimilar development. Simpor Pharma's focus on Halal pharmaceutical products aligns with Brunei's cultural and regulatory standards, opening avenues for Indian companies to collaborate in biosimilar production that meets these criteria. (mofe.gov.bn)

Additionally, Brunei's healthcare strategy emphasizes the sustainability of healthcare services through optimal use and innovation. This focus creates a conducive environment for introducing cost-effective biosimilars, which can enhance treatment accessibility and affordability.

3Demand Drivers

Brunei's healthcare spending per capita has shown a steady increase, reaching $665.87 in 2022, up from $657.90 in 2020. This upward trend indicates a growing investment in healthcare infrastructure and services, potentially expanding the demand for pharmaceutical imports. The country's strategic focus on excellence in healthcare services and the prevention and control of non-communicable diseases further drives the need for specialized medications.

Moreover, Brunei's aging population, with a life expectancy of 76.01 years for men and 80.8 years for women, contributes to an increased prevalence of chronic diseases, thereby elevating the demand for pharmaceutical products. The government's commitment to proactive and transparent governance in healthcare underscores the importance of addressing these health challenges through effective pharmaceutical solutions.

TransData Nexus Research · DGFT trade data analysisMar 2026

Trade Policy & Tariff Intelligence — India and Brunei

Tariff structure, trade agreements, IP and patent landscape

1Tariff & Duty Structure

Brunei's tariff structure for pharmaceutical formulations, classified under HS codes 3003 and 3004, is characterized by a Most-Favored-Nation (MFN) base rate of 0%. This rate applies to various pharmaceutical products, including those containing penicillins, amoxicillin, ampicillin, and other therapeutic agents. For instance, HS code 3003.10.10.00, covering amoxicillin-containing formulations, maintains a 0% MFN rate. Similarly, HS code 3004.10.15.00, pertaining to penicillin G formulations, also carries a 0% MFN rate. (fta.motir.go.kr)

Under the ASEAN-Australia-New Zealand Free Trade Area (AANZFTA), Brunei has committed to maintaining these 0% MFN rates for pharmaceutical products, ensuring that Indian pharmaceutical exports benefit from duty-free access to the Bruneian market. This preferential treatment is consistent across various pharmaceutical categories, including those for therapeutic or prophylactic uses, put up in measured doses or retail packaging. (mfa.gov.bn)

2Trade Agreements

As of March 2026, there is no specific Free Trade Agreement (FTA) between India and Brunei. However, both countries are members of the ASEAN-Australia-New Zealand Free Trade Area (AANZFTA), which facilitates trade among member nations, including Brunei. Under AANZFTA, Brunei has committed to maintaining 0% MFN rates for pharmaceutical products, ensuring that Indian pharmaceutical exports benefit from duty-free access to the Bruneian market. (mfa.gov.bn)

Additionally, Brunei is a member of the Regional Comprehensive Economic Partnership (RCEP), which includes India. The RCEP aims to enhance trade and economic integration among member countries, potentially impacting pharmaceutical trade dynamics. However, specific tariff commitments under RCEP for pharmaceutical products are not detailed in the available sources. Therefore, while Brunei's participation in these agreements may influence trade policies, the absence of a direct FTA between India and Brunei means that Indian pharmaceutical exports to Brunei primarily benefit from the MFN rates established under AANZFTA.

3IP & Patent Landscape

Brunei's intellectual property (IP) framework, including patent provisions, data exclusivity, and compulsory licensing, is not extensively detailed in the available sources. However, as a member of the World Trade Organization (WTO), Brunei is obligated to adhere to the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which sets minimum standards for IP protection and enforcement. This adherence implies that Brunei's IP laws are aligned with international norms, potentially affecting the importation and sale of generic drugs. For Indian pharmaceutical exporters, this means that while Brunei's IP laws may provide a level of protection for patented products, the specifics of patent enforcement, data exclusivity periods, and compulsory licensing provisions would require further investigation to fully understand their impact on generic drug imports.

TransData Nexus Research · Trade policy databasesMar 2026

Supply Chain & Logistics — India to Brunei Pharma Shipments

Shipping routes, port infrastructure, cold chain compliance

1Shipping Routes & Transit

Pharmaceutical shipments from India to Brunei primarily utilize sea and air transport. Sea freight is the most economical option for large shipments, with an average transit time of approximately 22 days. Air freight offers a faster alternative, with an average transit time of about 7 days, making it suitable for urgent deliveries.

The Red Sea disruption, which began in March 2026, has significantly impacted global shipping routes, including those from India to Brunei. This disruption has led to longer transit times and increased freight costs due to the need for alternative routes. Shippers are advised to monitor the situation closely and adjust their logistics plans accordingly to mitigate delays and additional expenses.

2Port Infrastructure

In India, key export ports handling pharmaceutical shipments to Brunei include Jawaharlal Nehru Port Trust (JNPT), Sahar Air Cargo Complex (INBOM4), and Delhi Air Cargo Complex (INDEL4). JNPT is a major seaport with extensive container handling facilities, while Sahar and Delhi Air Cargo Complexes are significant air cargo hubs equipped to handle pharmaceutical exports.

In Brunei, the primary import ports for pharmaceutical products are Bandar Seri Begawan and Muara. Bandar Seri Begawan serves as the main port, handling a substantial volume of imports, including pharmaceuticals. Muara port also contributes to the importation process, accommodating additional cargo volumes.

3Cold Chain & Compliance

Temperature-sensitive pharmaceutical products require strict cold chain management to maintain efficacy and safety. Depending on the specific product, this may involve maintaining temperatures between 2°C to 8°C (refrigerated), -18°C to -25°C (frozen), or even lower for certain biologics.

Compliance with Good Distribution Practice (GDP) is essential in the pharmaceutical supply chain. This includes proper documentation, monitoring of temperature conditions, and adherence to standard operating procedures (SOPs) throughout the logistics process. Utilizing validated packaging solutions, such as those incorporating dry ice, can help maintain the required temperature ranges during transit.

Ensuring compliance with the National Drug Regulatory Authority (NDRAs) in Brunei, which follows WHO-GMP standards, is crucial. This involves providing necessary documentation, adhering to labeling requirements, and ensuring that all pharmaceutical products meet the regulatory standards set by the authority.

TransData Nexus Research · DGFT port data, shipping intelligenceMar 2026

Market Opportunity Assessment — Brunei for Indian Pharma

Market size, healthcare system, growth outlook

1Market Size & Growth

Brunei's pharmaceutical market is projected to experience steady growth from 2025 to 2029, with an initial growth rate of 0.56% in 2025, increasing to 1.93% by 2029. This growth is driven by the country's commitment to providing comprehensive healthcare services to its citizens. The market is characterized by a high dependency on imports, with a significant portion of pharmaceutical products sourced from international suppliers. While specific data on the share of generic drugs in Brunei's pharmaceutical market is limited, the global trend indicates a growing adoption of generics due to their cost-effectiveness.

2Healthcare System

Brunei operates a universal healthcare system, fully funded by the government through its oil revenues. The Ministry of Health oversees the provision of free and comprehensive healthcare services to all residents, including preventive, diagnostic, therapeutic, and rehabilitative care. The public healthcare infrastructure comprises two major hospitals, five smaller hospitals, nine medical clinics, and seven dialysis centers. Additionally, there are 15 health centers and 40 health clinics that extend basic health services to rural areas, ensuring widespread access to medical care.

3Opportunity for Indian Exporters

The Indian pharmaceutical sector has established a presence in Brunei, with 28 exporters supplying a range of finished pharmaceutical formulations. In 2022, the total export value was $288,000 USD, with an average shipment value of $1,000 USD. The top products exported include Metformin Hydrochloride Extended Release Tablets, Levetiracetam Tablets, and Amoxicillin and Potassium Clavulanate formulations. The leading Indian exporters are Inventia Healthcare Limited, Jubilant Generics Limited, and Vea Impex (I) Private Limited. The primary Brunei buyers are Medicorp Sdn Bhd, Asterix United (B) Sdn Bhd, and another unnamed entity. Given Brunei's reliance on imported pharmaceuticals and its commitment to universal healthcare, there is a sustained demand for quality medications. Indian exporters can leverage this opportunity by focusing on high-demand therapeutic areas such as diabetes, epilepsy, and infectious diseases, aligning with Brunei's healthcare priorities. The projected steady growth of Brunei's pharmaceutical market suggests a favorable environment for expanding Indian pharmaceutical exports in the coming years.

TransData Nexus Research · Brunei healthcare dataMar 2026

Competitive Landscape — India vs Other Pharmaceutical Suppliers to Brunei

Competing origins, India's edge, challenges and threats

1Competing Origins

Brunei's pharmaceutical market is supplied by a diverse range of sources, including domestic manufacturers, regional producers, and international suppliers. While specific market share data is limited, it is evident that Brunei imports pharmaceutical products from various countries to meet its healthcare needs. For instance, Brunei imports pharmaceutical products from India, with a reported value of $812,800 in 2024. Additionally, companies like PHarMed Import & Export Pte Ltd, based in Singapore, export pharmaceutical products to Brunei, indicating regional trade dynamics. The presence of domestic pharmaceutical companies, such as Simpor Pharma Sdn Bhd, further contributes to the local supply chain. (bruneitrade.mofe.gov.bn) This diverse sourcing strategy ensures a steady supply of pharmaceutical products to Brunei, catering to the country's healthcare requirements.

2India's Competitive Edge

India's pharmaceutical industry offers several competitive advantages that enhance its position in the global market. Renowned for its cost-effectiveness, India provides high-quality pharmaceutical products at competitive prices, making it a preferred supplier for many countries. The industry's adherence to WHO-GMP standards ensures that products meet international quality benchmarks. Additionally, India's large English-speaking workforce facilitates seamless communication and collaboration with international partners. The country's extensive portfolio encompasses a wide range of pharmaceutical formulations, catering to diverse therapeutic areas and patient needs. These factors collectively bolster India's standing in the global pharmaceutical supply chain.

3Challenges & Threats

Despite its strengths, India's pharmaceutical exporters face several challenges in the Brunei market. Regulatory tightening by Brunei's National Drug Regulatory Authority (NDRA), which adheres to WHO-GMP standards, may pose compliance challenges for exporters. Intense competition from regional suppliers, particularly from China, can impact India's market share, as Chinese manufacturers often offer products at lower prices. Additionally, perceptions regarding product quality and the need for consistent supply chains are critical factors that influence Brunei's procurement decisions. Addressing these challenges requires strategic planning, adherence to regulatory standards, and a focus on maintaining product quality and reliability.

TransData Nexus Research · Global trade databasesMar 2026

FAQ — India to Brunei Pharmaceutical Trade

What is the total value of India's pharmaceutical export to Brunei?

India exported pharmaceuticals worth $287.7K to Brunei across 205 verified shipments.

Who are the top Indian pharmaceutical exporters to Brunei?

1. INVENTIA HEALTHCARE LIMITED — $83.9K. 2. JUBILANT GENERICS LIMITED — $29.6K. 3. VEA IMPEX (I) PRIVATE LIMITED — $28.0K. Total: 28 suppliers.

Which companies in Brunei import pharmaceuticals from India?

1. MEDICORP SDN BHD — $111.8K. 2. ASTERIX UNITED (B) SDN BHD — $29.6K. 3. TO THE ORDER OF INVOICE RAISED TO — $27.3K. 28 buyers total.

What pharmaceutical products does India export most to Brunei?

1. Proglutrol 500 (mal10110013a) ($83.9K, 29.2%); 2. Levetiracetam 500 MG Tablets Batch No Lv225001a Mfg Date 01.04.2025 Exp Date 31… ($29.6K, 10.3%); 3. Amoxicillin and Potassium Clavulanate Fo ($27.8K, 9.7%); 4. Pharmaceutical Drugs and Medicine - Carbopa - 450 450mg/45ml Vial As Per Invoice ($13.7K, 4.7%); 5. Contain Medicines Harmless Pharmaceutical Products - Contrapaque 350injection (… ($13.3K, 4.6%)

Which ports handle pharmaceutical shipments from India to Brunei?

Export: JNPT, SAHAR AIR CARGO ACC (INBOM4), DELHI AIR CARGO ACC (INDEL4), SAHAR AIR, BANGALORE ICD (INWFD6). Import: BANDAR SERI B, MUARA, Muara, BENNETTSVI, DAR ES SALAM (DARESS.

Why does Brunei import pharmaceuticals from India?

India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $287.7K corridor reflects quality compliance and pricing advantages.

What certifications do Indian pharmaceutical exporters need to supply Brunei?

WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.

What is the average shipment value for India to Brunei pharmaceutical trade?

$1.4K per consignment across 205 shipments.

How many Indian pharmaceutical companies export to Brunei?

28 Indian companies. Largest: INVENTIA HEALTHCARE LIMITED with $83.9K.

How can I find verified Indian pharmaceutical suppliers for Brunei?

TransData Nexus covers 28 active exporters with shipment history and trade values at transdatanexus.com.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Data Source: Indian Customs (DGFT) export shipping bill records covering all pharmaceutical shipments from India.
2.Country Matching: Shipments to Brunei identified using destination country codes from customs declarations.
3.Statistical Normalization: Values are statistically normalized to remove outlier transactions and ensure accurate market share representation.
4.Coverage: 205 verified shipments from 28 Indian exporters to 28 Brunei buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

28 Exporters

28 buyers tracked

Expert-Reviewed

By pharmaceutical trade specialists

India to Brunei Pharmaceutical Export